AlphaCrest Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

AlphaCrest Capital Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-8,597	Closed	-$511K	–	1205
2020 Q3	$511K	Buy	+8,597	New	+$587K	0.06%	572
2020 Q2	–	Sell	-5,806	Closed	-$263K	–	1017
2020 Q1	$263K	Buy	+5,806	New	+$329K	0.03%	842
2019 Q4	–	Sell	-6,160	Closed	-$383K	–	1315
2019 Q3	$383K	Buy	+6,160	New	+$387K	0.02%	1031
2019 Q2	–	Sell	-3,597	Closed	-$282K	–	1087
2019 Q1	$282K	Buy	+3,597	New	+$273K	0.04%	675

Other funds holding LGND

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

AlphaCrest Capital Management's LGND Position: Q4 2020 in Review

AlphaCrest Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q4 2020, closing a stake of 8,597 shares — an estimated $511K sold.

AlphaCrest Capital Management first reported a position in LGND in Q1 2019 and held it in 4 quarters. The position peaked at $511K in Q3 2020. 242 funds tracked by Wall St. Rank hold LGND as of Q4 2020.

AlphaCrest Capital Management reported no remaining Ligand Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
AlphaCrest Capital Management sold 8,597 Ligand Pharmaceuticals shares in Q4 2020, an estimated $511K.
AlphaCrest Capital Management first reported a position in Ligand Pharmaceuticals in Q1 2019 and held it in 4 quarters.
AlphaCrest Capital Management's Ligand Pharmaceuticals position peaked at $511K in Q3 2020.
242 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2020.

Based on AlphaCrest Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.